Company
Headquarters: New Taipei City, Taiwan
CEO: Dr. Lee-Cheng Liu
TW$31.31 Billion
TWD as of Jan. 1, 2024
US$1.02 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
EirGenix Inc. operates as a contract development and manufacturing company Taiwan and internationally. Its services include cell line development and cell bank manufacturing, process development, analytical sciences and quality control, cGMP manufacturing, and antibody drug conjugate. The company was founded in 2012 and is based in New Taipei City, Taiwan.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
EirGenix, Inc. has the following listings and related stock indices.
Stock: TWSE: 6589 wb_incandescent